Several similar clinical trials (NCT04701307, NCT04334941, NCT04538378, and NCT03958045) are currently recruiting SCLC patients to evaluate the use of PARPi and anti-PD1 antibody combination therapy (Table 3). The gene discussed is PDCD1; the disease is small cell lung carcinoma.